Company · CIK 0001649904 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
RHYTHM PHARMACEUTICALS, INC. · RYTM
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 SForm 4 → | Sep 14, 7:37 pm EDT | David P MeekerPresident and CEO, Director | 50,000 | $102.67 | $5,133,442 | 239,258 | −17.3% | 10b5-1 |
| Sep 14, 2026 MForm 4 → | Sep 14, 7:37 pm EDT | David P MeekerPresident and CEO, Director | 50,000 | $6.05 | $302,500 | 289,258 | — | 10b5-1 |
| Aug 31, 2026 SForm 4 → | Sep 1, 4:22 pm EDT | Hunter C SmithChief Financial Officer | 62,774 | $105.46 | $6,619,913 | 114,024 | −35.5% | 10b5-1 |
| Aug 31, 2026 MForm 4 → | Sep 1, 4:22 pm EDT | Hunter C SmithChief Financial Officer | 57,187 | $25.79 | $1,474,853 | 176,798 | — | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 6:00 pm EDT | Joseph ShulmanChief Technical Officer | 5,079 | $119.75 | $608,210 | 15,915 | −24.2% | 10b5-1 |
| Aug 13, 2026 MForm 4 → | Aug 17, 6:00 pm EDT | Joseph ShulmanChief Technical Officer | 2,024 | $6.80 | $13,763 | 20,994 | — | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 17, 5:57 pm EDT | Alastair GarfieldChief Scientific Officer | 7,763 | $117.57 | $912,703 | 2,295 | −77.2% | 10b5-1 |
| Aug 13, 2026 SForm 4 → | Aug 14, 7:04 pm EDT | Jennifer Kayden LeeEVP, Head of North America | 75,834 | $117.38 | $8,901,531 | 0 | −100% | 10b5-1 |
| Aug 13, 2026 MForm 4 → | Aug 14, 7:04 pm EDT | Jennifer Kayden LeeEVP, Head of North America | 56,601 | $17.62 | $997,037 | 75,834 | — | 10b5-1 |
| Aug 12, 2026 SForm 4 → | Aug 14, 7:01 pm EDT | Yann MazabraudEVP, Head of International | 57,000 | $116.15 | $6,620,575 | 55,655 | −50.6% | 10b5-1 |
| Aug 12, 2026 MForm 4 → | Aug 14, 7:01 pm EDT | Yann MazabraudEVP, Head of International | 46,625 | $6.80 | $317,050 | 112,655 | — | 10b5-1 |
| Jul 1, 2026 FMForm 4 → | Jul 2, 4:52 pm EDT | Alastair GarfieldChief Scientific Officer | 6,595 | $110.41 | $237,382 | 10,058 | — |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 MForm 4 → | Sep 14, 7:37 pm EDT | David P MeekerPresident and CEO, Director | 50,000 | — | — | 15,431 | — | 10b5-1 |
| Aug 31, 2026 MForm 4 → | Sep 1, 4:22 pm EDT | Hunter C SmithChief Financial Officer | 57,187 | — | — | 3,813 | — | 10b5-1 |
| Aug 17, 2026 AForm 4 → | Aug 18, 5:35 pm EDT | Manher JoshiChief Medical Officer | 75,000 | — | — | 25,000 | — | |
| Aug 13, 2026 MForm 4 → | Aug 17, 6:00 pm EDT | Joseph ShulmanChief Technical Officer | 2,024 | — | — | 5,945 | — | 10b5-1 |
| Aug 13, 2026 MForm 4 → | Aug 14, 7:04 pm EDT | Jennifer Kayden LeeEVP, Head of North America | 56,601 | — | — | 0 | — | 10b5-1 |
| Aug 12, 2026 MForm 4 → | Aug 14, 7:01 pm EDT | Yann MazabraudEVP, Head of International | 46,625 | — | — | 35,875 | — | 10b5-1 |
| Jul 1, 2026 MForm 4 → | Jul 2, 4:52 pm EDT | Alastair GarfieldChief Scientific Officer | 4,445 | — | — | 8,888 | — |